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Abstract
BACKGROUND—Cognitive-behavioral therapy (CBT) and selective serotonin reuptake 
inhibitors (SSRIs) are the two first-line treatments for depression, but little is known about their 
effects on quality of life.
AIMS—To investigate the efficacy of these two interventions for depression on quality of life 
(QOL).
METHOD—A meta-analysis was conducted to examine changes in QOL in adults with major 
depressive disorder who received CBT (24 studies examining 1,969 patients) or SSRI treatment 
(13 studies examining 4,286 patients) for their depression.
RESULTS—Moderate improvements in QOL from pre to post-treatment were observed in both 
CBT (Hedges’ g = 0.63) and SSRI (Hedges’ g = 0.79) treatments. The effect size remained stable 
over the course of the follow-up period for CBT. No data were available to examine follow-ups in 
the SSRI group. QOL effect sizes decreased linearly with publication year, and greater 
improvements in depression were significantly associated with greater improvement in QOL for 
CBT, but not for SSRIs.
CONCLUSION—CBT and SSRIs for depression were both associated with moderate 
improvements in QOL, but are possibly caused by different mechanisms.
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Depression is one of the most costly and common disorders worldwide (World Health 
Organization, 2005). The lifetime prevalence rate of DSM-IV major depressive disorder 
(MDD) in the United States is 16.2% and the 12-month prevalence rate is 6.6% (Kessler, R. 
C. et al., 2003). The large economic burden is driven by its high prevalence rate and 
debilitating nature of the illness (Greenberg, Fournier, Sisitsky, Pike & Kessler, 2015; 
Marcus & Olfson, 2010). MDD has a significant impact on the patient’s quality of life 
(QOL). Quality of life refers to subjective well-being, life satisfaction, perceptions of social 
relationships, physical health, economic status, and functioning in daily activities and work 
and is typically assessed through subjective views of one’s life circumstances, perceptions of 
mental and physical health, social and family relationships, and functioning at work and 
home (Angermeyer & Kilian, 2006).
Effective treatments of this pervasive and chronic disorder can lead to a reduction in 
depressive symptoms, improvement of psychosocial functioning, and greater QOL 
(Merikangas, et al., 2007; Angermeyer & Katschnig, 2006). However, the treatment effects 
on QOL have not received nearly as much attention as clinical measures of depression. It is 
possible that regulatory agencies have not placed much value on QOL measures because 
they are not primary outcome measures in clinical trials, including those leading to drug 
marketing approval.
Although depression severity is correlated with QOL impairment, (Judd, et al., 2000) the 
changes in QOL are not fully accounted for by changes in depression, (Hirschfeld, et al., 
2002) and QOL changes more slowly than symptoms of depression (Trivedi, 2006). 
Furthermore, treatments that reduce depression symptoms do not necessarily result in 
improved QOL. A meta-analysis examining adjunctive atypical antipsychotic treatment for 
depression, for instance, showed that while observer ratings of depression decreased with 
pharmacotherapy use, there was little evidence of improvement in patients’ QOL 
(Spielmans, Berman, Linardatos, Rosenlicht, Perry, & Tsai, 2013). Additionally, a meta-
analysis investigating the efficacy of antidepressants for depressed youths demonstrated that 
despite improvement in clinician-rated depression symptoms following the use of 
antidepressants, patients did not exhibit improvement in overall well-being and QOL 
(Spielmans & Gerwig, 2014).
It has been suggested that psychotherapy might be more effective for changing QOL because 
it directly targets general well-being, whereas pharmacotherapy more indirectly targets QOL 
by focusing on symptoms (Angermeyer & Kilian, 2006; Gladis, Gosch, Dishuk, & Crits-
Christoph, 1999) but there is little empirical data to support this argument. For instance, 
Farabaugh et al. (2015) randomized depressed individuals to 12 weeks of CBT (n = 15) or 
escitalopram (n = 11). The authors found no statistically significant differences between 
treatment groups on any of the outcome measures, including QOL. The study by Orjuela-
Rojas et al. (2015) randomized patients with temporal lobe epilepsy to receive 12 weeks of 
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CBT (n = 7) or SSRI (n = 8) for the treatment of major depressive disorder. After treatment, 
both groups showed improved QOL and reduced severity of depression symptoms, with no 
statistically significant group differences.
Numerous guidelines, including the Practice Guidelines by the American Psychiatric 
Association (Gelenberg, et al., 2010) recommend cognitive behavioral therapy (CBT) and 
selective serotonin reuptake inhibitors (SSRIs) as treatment for depression. While there are 
other effective psychological short-term treatments for depression that are not part of the 
general CBT family, we chose to limit our analyses to CBT for a number of reasons. First, 
the number of clinical trials examining the efficacy of CBT for depression is very large 
(Hofmann et al., 2012), providing a large sample of potential studies. Second, the clinical 
trials involving CBT typically show a relatively high rigor or methodological quality; and 
third, restricting the review to CBT reduces the heterogeneity of empirically supported 
psychological therapies.
The aim of this study was to examine the effects of CBT and SSRIs for depression on 
quality of life. This is an important aim, because an effective treatment for a common mental 
disorder, such as depression, should ideally not be limited to only symptom improvement 
but also include enhancing the person’s QOL. Using a meta-analytic approach, we 
hypothesized that both treatments would be associated with improvements in quality of life. 
Due to the small number of available studies directly comparing CBT and SSRIs, we did not 
predict that one treatment modality would be associated with greater improvements in QOL 
than the other. Instead, we examined the effects of both treatments on QOL independently.
Methods
Search
A search of PubMed and PsycINFO databases for articles published from 1994 to the 
present was conducted on June 20, 2014, and then updated October 17, 2016. We used a 20-
year time span to focus on the relatively recent literature and to limit the heterogeneity of the 
studies in terms of treatment approach, diagnostic criteria, and measures used for depression 
and QOL. The following three sets of search terms were used simultaneously: ((quality of 
life OR quality-of-life)) AND (((((cognitive therapy OR cognitive behavio* therapy) OR 
(behavior therapy OR behavio* therapy)) OR (cognitive-behavioral OR cognitive-
behavioural)) OR (pharmacological OR pharmacotherapy)) AND (depression OR 
depressive)). The initial search produced 3,862 results, with 3,665 studies remaining after 
duplicates were excluded. In accordance with the guidelines set forth in Preferred Reporting 
Items for Systematic Reviews and Meta-analysis Protocols (Moher, et al., 2015). the 
protocol for this meta-analysis was registered in with the International Prospective Register 
of Systematic Reviews (PROSPERO) on July 10, 2014, and was last updated on January 16, 
2015 (registration number CRD42014009831).
Study Selection
Studies were selected by the second through fourth authors and a team of independent 
trained assessors. Studies were included in the present meta-analysis if: 1) at least one 
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treatment condition consisted of CBT or treatment with an SSRI; 2) they included a sample 
diagnosed with current major depression; 3) they included a sample of adults at or above the 
age of 18; 4) they included an adequate measure of QOL at pre- and post-intervention. 
Following the recommendation of Moons, Budts and De Geest (2006), we conceptualized 
QOL in terms of life satisfaction. Therefore studies with QOL measures that exclusively 
focused on mental or physical symptoms or health status without tapping a subjective aspect 
of satisfaction with one’s life were excluded. QOL measures that do not meet this criteria 
might be more adequately understood of as assessments of health status, which has been 
shown to be conceptually distinct from QOL (Smith, Avis, & Assmann, 1999). We also 
confirmed that all included QOL measures had demonstrated adequate reliability and 
validity; and 5) they provided sufficient data on the intervention of interest for calculating an 
effect size to use in our meta-analysis.
Studies were excluded if: 1) major depression was secondary to another psychiatric 
condition; 2) the data in one study overlapped with data reported in another study considered 
for inclusion; 3) CBT or SSRI was administered in conjunction with another active 
treatment. In cases of disagreement, the authors discussed the case until consensus was 
reached. If the data necessary to calculate an effect size were not reported, we requested 
these data from the corresponding author.
Data Extraction
For each selected study, we extracted data on QOL and depression symptoms at pre-
treatment, post-treatment, and 6-month follow-up (or closest available follow-up date if 
included in study) for the CBT or SSRI treatment arms, along with data from control 
conditions if included. In addition, we extracted data on sample and study characteristics, 
including sample size, length of treatment, SSRI type and dosage, CBT treatment modality 
(e.g. individual, group, or computer-based) and dosage (i.e. hours of therapy), gender, age, 
psychiatric medication use (for CBT samples) and medical and psychiatric comorbidity. In 
studies where more than one active treatment condition was examined, data from the more 
intensive form of therapy was used (e.g. individual rather than group therapy). If a study 
used multiple eligible measures of QOL, we extracted data from the measure that was in 
closer accordance with our operational definition of QOL. Specifically, we selected the 
Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ; Endicott, Nee, 
Harrison, & Blumenthal, 1993) over the Short-Form 36 Health Survey (SF-36; Ware & 
Sherbourne, 1992) and the Spitzer Quality of Life Index, and the Quality of Life Inventory 
(QOLI; Frisch et al., 2005) over the SF-36. When studies utilized multiple measures of 
depression, we chose clinician-administered scales over self-report measures. Data were 
extracted on two separate occasions by independent raters and compared to ensure accuracy, 
with discrepancies resolved by the second and third authors.
Risk of Bias Assessment
In accordance with the Cochrane guidelines for systematic reviews, (Higgins & Green, 
2011) we assessed study quality with the Cochrane Collaboration’s tool for assessing risk of 
bias (Higgins & Altman, 2008). This tool involves assessing each study as containing a high, 
low or unclear level of bias risk in a number of domains (sequence generation, allocation 
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concealment, incomplete outcome data, and selective outcome reporting). Although this tool 
was initially designed for assessment of randomized controlled trials, the Cochrane 
guidelines specify that it may be adapted for the evaluation of non-randomized trials 
(Higgins, & Green, 2011). In doing so, we assigned non-randomized trials a high risk rating 
in the sequence generation category. Following recommendations from the Cochrane 
guidelines, a total bias assessment was created for each study such that an ‘unclear’ rating in 
any category meant an ‘unclear risk’ overall rating, a ‘high’ rating in any category lead to a 
‘high risk’ overall rating, and ‘low risk’ studies had to be rated as ‘low’ in all four 
categories. The second and third authors independently rated each study and then met to 
resolve any discrepancies. Inter-rater reliability for the total bias assessment was strong 
(Kappa = .80; SE = .09).
Quantitative Data Synthesis
We used a random effects model because of the heterogeneity within the studies. Within-
group and controlled effect sizes were calculated using Hedges’ g (Hedges & Olkin, 1985). 
Specifically, within-group effect sizes reflect pre- to post-treatment changes, and controlled 
effect sizes represent differences in efficacy between the treatment and control conditions. 
To compute the within-group effect size, the following formulas were utilized: 
, such that  reflects the pre-treatment mean,  reflects the 
post-treatment mean, Sdifference reflects the standard deviation of the difference, and r 
reflects the correlation between pre-treatment and post-treatment scores. Hedges’ g was 
computed by multiplying d with correction factor , such that df 
represents the degrees of freedom to estimate the within-group standard deviation. The 
controlled effect sizes were computed using the following formula: 
, such that is the 
mean pre- to posttreatment change, SD is the standard deviation of post-treatment scores, n 
is the sample size, TREAT refers to the active treatment condition (i.e., CBT or SSRI), and 
CONT refers to the control condition. Following Rosenthal (1984), we estimated the pre-
post correlation to be r = .70.
To investigate potential moderator effects on QOL outcome, we employed the between-
group heterogeneity statistic (QB) recommended by Hedges and Olkin (Hedges & Olkin, 
1985) and meta-regression procedures for categorical and continuous moderators, 
respectively. Moderators of interest included both treatment characteristics (i.e., study year, 
treatment dose, risk of bias, assessment type, treatment format, sex distribution, frequency of 
contact with study physician, concomitant medication, completer percentage) and clinical 
characteristics (i.e., depression symptom improvement and comorbidity with a medical 
condition). In addition, for CBT studies we also investigated whether inclusion of patients 
stable on psychiatric medication predicted QOL outcome, and for SSRI studies, we tested 
the impact of frequency of visits with study physician.
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To examine the presence of publication bias, we inspected the funnel plot. In addition, we 
used the fail-safe N method to determine the number of additional studies with a null result 
needed to reduce the overall effect size to non-significance (Rosenthal, 1991). If the fail-safe 
N exceeds 5 multiplied by K (i.e., the number of studies in the meta-analysis) + 10, then the 
results may be considered statistically robust. We also examined the funnel plot to evaluate 
symmetry relative to the mean effect size, with greater symmetry corresponding to decreased 
likelihood of publication bias. To complement funnel plot inspection, the trim and fill 
method (Duval, & Tweedie, 2000) was utilized to determine the nature of potential 
publication bias and compute an imputed effect size that accounts for it. Furthermore, we 
examined Egger’s regression intercept to determine whether results might be biased as a 
consequence of study number. Due to space constraints, we limited the funnel plot analysis 
to only the main analyses. All meta-analytic procedures were conducted in Comprehensive 
Meta-Analysis, Version 3 (Comprehensive Meta-Analysis, 2016).
Results
Study Flow and Characteristics
The flow diagram in Figure 1 shows the number of studies excluded at each stage of study 
selection, and the reasons for exclusion. Of the 4,426 unique studies initially identified, 37 
(24 CBT, 13 SSRI) were determined to be eligible and included in the final analysis. 
Together these studies examined 1,969 participants receiving CBT and 4,286 participants 
receiving SSRI treatment. Of note, only two studies directly examined the effects of both 
SSRI and CBT for depression on QOL (Farabaugh et al., 2015; Orjuela-Rojas, Martínez-
Juárez, Ruiz-Chow & Crail-Melendez, 2015). In order to avoid double counting these 
studies by using them for analyses of both treatment modalities, we excluded it from our 
analyses.
Study characteristics are presented in Table 1. Results from our risk of bias assessment 
showed that most studies had an unclear (10 CBT, 4 SSRI) or high risk (11 CBT, 8 SSRI) 
bias, with one SSRI and three CBT studies determined to be low risk in all four of the rated 
categories. There was no difference in bias ratings between intervention types (Fisher’s 
Exact Test = 0.85, p = n.s.). In addition, no difference was found in the percentage of 
patients who completed treatment in CBT (M = 77.39, SD = 10.19) and SSRI studies (M = 
82.02, SD = 15.02; t (29) = 0.84, p = n.s.).
Across intervention types, the mean study sample consisted of 65.81% female participants 
(SD = 18.20), with a greater percentage in CBT studies (M = 71.33, SD = 13.46) than SSRI 
studies (M = 55.62, SD = 21.73; t(35) = 2.72, p < .05). The mean age of each study sample 
was 45.39 (SD = 9.73), with no difference between CBT (M = 46.46, SD = 9.90) and SSRI 
studies (M = 43.25, SD = 9.42; t(34) = 0.93, p = n.s.). Mean treatment duration across 
intervention type was 11.94 weeks (SD = 5.40), and was equivalent in CBT (M = 11.36 
weeks, SD = 4.35) and SSRI studies (M = 12.92 weeks, SD = 6.91; t(17.71) = −0.82, p = 
n.s.). Only one SSRI study reported data on the frequency of psychiatric comorbidity 
(Saveanu, et al., 2015). Among the 15 CBT studies reporting such data, the mean percentage 
of participants with at least one comorbid condition was 55.80% (SD = 20.16). Of the 20 
CBT studies that provided information on psychiatric medication use, 15 allowed 
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participants to enter the study if stable on psychiatric medication, and on average 47.00% 
(SD = 32.56) of participants used medication. Only four of the 13 SSRI trials provided 
information on psychotherapy use among study participants, with all four trials excluding 
concomitant psychotherapy treatment during the trial. Ten studies reported follow-up data, 
with the mean follow-up assessment being 5.0 months post-treatment (SD = 1.81; range = 
1–7 months).
To determine whether baseline symptom severity influenced the effect sizes of the two 
interventions, we examined differences in baseline depression severity across interventions. 
For interventions using the BDI-II as the primary outcome measure, no differences were 
found between CBT (M = 28.00, SD = 5.64) and SSRI treatments (M = 22.00, SD = 3.06; 
t(9) = 1.01, p = n.s.). Likewise, for interventions using the HAM-D as the primary outcome 
instrument, no differences were found between CBT (M = 18.73, SD = 3.06) and SSRI 
treatments (M = 20.89, SD = 2.78; t(11) = 1.09, p = n.s.).
Quantitative Data Synthesis
Treatment Effects on Depression
Pre-post within-group effects: For the within-group effects of treatment of depression, one 
outlier (Farabaugh, et al., 2015) (Hedges’ g = 5.16) was identified and removed. The pre-
post within-group random effect size on depression symptoms was Hedges’ g = 1.30 (95% 
CI: 1.16–1.45, z = 17.81, p < .0001). The fail-safe N for measures of depression was 38,715 
(z = 65.22), using an alpha level of .05. The fail-safe N values for SSRIs and CBT were 
7,427 (z = 48.79) and 12,210 (z = 45.20), respectively. The Egger's regression intercept was 
not significant (intercept = 1.87, 2-tailed p = n.s.), suggesting that the parameter estimates 
were not influenced by the number of studies. The Q-value was significant (Q-value = 
454.67, p < 0.01), and the I2 value was 95.16, suggesting considerable heterogeneity.
Pre-follow-up within-group effects: To examine the long-term effects of the treatments on 
depression, we examined the change in depression from pre-treatment to follow-up. Ten 
studies, all of which investigated CBT interventions, included follow-up data. One study 
with an effect size that was more than 2 standard deviations above the mean of the effect 
sizes of the other studies was identified (Qiu, et al., 2013) and removed from subsequent 
analyses (Hedges’ g = 3.73). The random effects meta-analysis yielded an effect size of 
Hedges’ g = 1.33 (95% CI: 0.99–1.67, z = 7.82, p < .0001). The fail-safe N was 1,265 (z = 
23.32). The Egger's regression intercept was significant (intercept = 6.66, 2-tailed p < 0.05), 
suggesting that the parameter estimates could be influenced by the number of studies. The 
Q-value was significant (Q-value = 83.92, p < 0.01), and the I2 value was 90.47, suggesting 
considerable heterogeneity.
Pre-post controlled effects: To examine the treatment effect on depression in controlled 
studies, we examined the controlled effect size and found an overall large effect of Hedges’ 
g = 1.21 (95% CI: 0.55–1.87, z = 3.59, p < .0001). The fail-safe N was robust with N = 221 
(z = 11.41); however, the Egger's regression intercept was significant (intercept = 1.71, 2-
tailed p < 0.05). The Q-value was significant (Q-value = 105.96, p < 0.01), and the I2 value 
was 94.34, suggesting considerable heterogeneity.
Hofmann et al. Page 7
Cogn Behav Ther. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Treatment Effects on Quality of Life
Pre-post within-group effects: For the within-group analysis, one outlier with 2 standard 
deviations above the mean (Hedges’ g = 3.28) was identified (Åberg-Wistedt, Ågren, 
Ekselius, Bengtson & Åkerblad, 2000). and removed from subsequent analyses. The random 
effects meta-analysis yielded an overall QOL effect size of Hedges’ g = 0.69 (95% CI: 0.61–
0.78, z = 15.52, p < .0001). The fail-safe N analyses for the CBT and SSRI treatments were 
robust with N = 5,282 (z = 29.14) and 5,233 (z = 39.37), respectively. Likewise, the Egger's 
regression intercept was not significant for all studies (intercept = −0.63, 2-tailed p = n.s.). 
The Q-value was significant (Q-value = 381.24, p < 0.01), and the I2 value was 90.56, 
suggesting considerable heterogeneity.
Using the trim and fill method (Figure 2), 5 studies would need to fall to the left of the mean 
(i.e., have an effect size smaller than the mean) and 0 studies would need to fall to the right 
of the mean (i.e., have an effect size larger than the mean) to make the overall random-
effects plot symmetrical. The random-effects model for the new imputed mean effect size 
revealed a Hedges’ g = 0.68 (95% CI: 0.66–0.70).
Pre-follow-up within-group effects: Ten studies, all of which investigated CBT 
interventions, assessed QOL at follow-up. The random effects analysis yielded an effect size 
of Hedges’ g = 0.72 (95% CI: 0.48–0.97, z = 5.76, p < .0001), which did not significantly 
differ from the CBT pre-post within-group effect size (QB = 0.09, df = 1, p = n.s.). The fail-
safe N was 614 (z = 15.47); however, the Egger's regression intercept was significant 
(intercept = 6.26, 2-tailed p < 0.05). The Q-value was significant (Q-value = 79.06, p < 
0.01), and the I2 value was 88.62, suggesting considerable heterogeneity.
Pre-post controlled effect sizes: Eight of the trials included a non-active control or 
comparison group, including pill placebo, attention control, clinical monitoring, online 
discussion groups, treatment as usual, and waitlist. In total, these controlled trials together 
yielded a QOL controlled effect size of Hedges’ g = 0.29 (95% CI: 0.12–0.47, z = 3.31, p < .
01). Using an alpha level of .05, the fail-safe N for measures of QOL was 43 (z = 4.94). 
Because this N is smaller than 5k + 10, the controlled effect sizes cannot be considered 
statistically robust. However, the Egger's regression intercept was not significant (intercept = 
0.21, 2-tailed p = n.s.), suggesting that the parameter estimates were not influenced by the 
number of studies. The Q-value was not significant (Q-value = 13.63, p = 0.06), and the I2 
value was 48.63, suggesting moderate heterogeneity.
Moderator Analyses—Results revealed no significant relationship between pre-post QOL 
effect sizes and study quality (QB = 0.37, df = 2, p = n.s.) or percentage of patients who 
completed treatment (B = −0.01, SE = 0.01, p = n.s). Moreover, comorbidity with a medical 
disorder did not significantly moderate QOL effect sizes (QB = .25, df = 1, p = n.s.), nor did 
sex distribution (B = −0.003, SE = 0.00, p = n.s.).
For both SSRI and CBT interventions, treatment efficacy was not moderated by dosage (B = 
0.008, SE = 0.01, p = n.s.) or total treatment hours (B = −0.004, SE = 0.01, p = n.s.). The 
current results suggest that neither delivery format of CBT (i.e., individual, group, computer-
based) (QB = 1.63, df = 2, p = n.s.),type of SSRI (QB = 5.19, df = 5, p = n.s.), nor frequency 
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of contact with study physician in SSRI studies (B = 0.001, SE = 0.07, p = n.s.) moderated 
improvement in QOL. Moreover, the efficacy of CBT on QOL was not moderated by 
whether a study included patients who were on a stable dose of psychiatric medication (QB 
= 0.32, df = 1, p = n.s.). We also examined likelihood of being placed in placebo condition 
as predictor of pre-post effect size in SSRI studies, and found no effect (B = 0.00, SE = 0.00, 
p = n.s.).
However, quality of life effect sizes were moderated by publication year (B = −0.02, SE = 
0.01, p < 0.05), indicating that the effect sizes decreased linearly with time. The decrease in 
effect size across time was likely not accounted for by diminishing study quality or sample 
size, Furthermore, of the 6 most recently published studies, all of them still had statistically 
significant within-group effect sizes. In fact, of the 36 studies, only 2 of them (Paile-
Hyvärinen, Wahlbeck, & Eriksson, 2003; Vilhauer, Cortes, Moali, Chung, Mirocha, & Ishak, 
2013) had non-significant within-group effect sizes. Improvement in QOL was also 
significantly moderated by improvement in depression (B = 0.22, SE = 0.05, p < .0001). 
Depression improvement was positively associated with QOL improvement for those who 
received CBT (B = 0.21, SE = 0.06, p < .0001), whereas no significant relationship occurred 
for those receiving SSRIs (B = 0.21, SE = 0.13, p = n.s.). However, there was no significant 
interaction effect of changes in depression and intervention type on QOL improvement (B = 
− 0.13, SE = 0.23, p = n.s.).
Based on prior research demonstrating differential effect sizes resulting from the use of 
clinician-administered versus self-report measures of depression, (Cuijpers, Li, Hofmann, & 
Andersson, 2010) we investigated type of assessment instrument as a moderator of 
depression outcome. Consistent with such research, our analyses similarly showed that 
clinician administered measures yielded larger effect sizes (Hedges’ g = 1.56) than did self-
report instruments (Hedges’ g = 1.01) (QB = 12.74, df = 1, p < 0.05.). Furthermore, the type 
of assessment instrument for depression moderated the relationship between depression 
effect sizes and QOL effect sizes (B = −0.37, SE = 0.18, p < 0.05.). Specifically, the 
relationship between depression and QOL improvement was weaker for clinician 
administered measures (B = 0.13) than for self-report measures (B = 0.51).
Discussion
To examine the effects of the two most common treatments for depression (SSRI and CBT) 
on QOL, we conducted a meta-analytic review. Our initial search produced 3,665 unique 
studies. Of those, 37 studies (24 CBT, 13 SSRI) examining 1,969 participants receiving CBT 
and 4,286 participants receiving SSRI treatment were used for this meta-analytis. Only two 
studies directly examined the effects of SSRI and CBT for depression on QOL (Farabaugh, 
et al., 2015; Orjuela-Rojas et al., 2015), and as described above were not included in the 
analysis. Therefore, this research was not designed to directly compare the effects of CBT 
vs. SSRIs for depression on QOL. Rather, the present study provides an assessment of the 
size of the effect that SSRIs and CBT have on QOL in patients treated for depression, as 
well as the strength of the evidence for such effects.
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Results showed that both SSRIs and CBT were associated with large reductions in QOL 
from pre to post-treatment, and small effects compared to control treatments. Furthermore, 
computer-based, individual, and group-based CBT for depression similarly improved QOL. 
A small number of studies (all of them were CBT trials) also included follow-up data and 
the results showed that this effect was maintained over a follow-up period of 1 to 7 months, 
supporting the current practice guidelines (Gelenberg, et al., 2010). Together, these results 
suggest that the effects of SSRIs and CBT for MDD extend beyond symptoms of depression, 
broadly impacting patients’ quality of life.
The primary analysis showed that QOL significantly improved after SSRIs (Hedges’ g = 
0.79) and CBT (Hedges’ g = 0.63) for depression. Similar effects on QOL were observed in 
other studies with CBT (Hofmann, Wu, & Boettcher, 2014) and pharmacotherapy 
(Hofmann, Wu, Boettcher, & Sturm, 2014) for anxiety disorders. Of note, a significant 
portion of participants in most CBT trials (45%) began treatment while also receiving some 
form of pharmacotherapy. Although patients were stabilized on their medication throughout 
the CBT treatment, it is possible that the medication already enhanced the patients’ QOL, 
making it more difficult for CBT to further improve QOL. On the other hand, the majority of 
SSRI trials (9 of 13) did not provide information on concomitant psychotherapy use, making 
it difficult to evaluate whether SSRI response could have been influenced by additional 
treatment.
Interestingly, improvement in depression was positively associated with changes in QOL 
only for patients who received CBT but not for those who received SSRIs. This is somewhat 
consistent with other meta-analytic research on psychotherapy for depression showing that 
changes in mental health-related quality of life over the course of treatment were partially 
accounted for by changes in depressive symptoms (Kolovos, Kleiboer & Cuijpers, 2016). It 
is possible that CBT improves QOL primarily by reducing symptoms of depression, whereas 
SSRIs are more broad-band therapies that target a multitude of psychiatric problems, 
including anxiety and stress (Gorman, & Kent, 1999). Combining SSRIs and CBT might 
result in a more complete and long-lasting improvement by not only reducing depression but 
also improving the patient’s QOL. Future combination studies with mediation analyses that 
examine the causal pathway would provide valuable data to examine this possible 
explanation.
Although only a minority of studies clearly demonstrated a low risk of bias, risk of bias was 
unrelated to the effect size estimates of the interventions on QOL in the present study. The 
suboptimal risk of bias ratings obtained in the current meta-analysis are also in accordance 
with those found in other large scale meta-analyses of CBT for depression (Cristea, Huibers, 
David, Hollon, Andersson, & Cuijpers, 2015), which is not uncommon in systematic reviews 
using the Cochrane Collaboration’s Risk of Bias tool (Armijo‐Olivo, Stiles, Hagen, Biondo, 
& Cummings, 2012; Robertson, Ramsay, Gurung, Mowatt, Pickard, & Sharma, 2015; Sinha, 
Craig, Sureshkumar, Hayen, & Brien, 2015). Further, we observed no difference in the risk 
of bias between CBT and SSRI trials. Nevertheless, the small number of high quality studies 
is clearly a limitation; more high quality studies in the depression field are needed. In 
addition, our analyses showed that treatment intensity, type of SSRI sample size, 
comorbidity, and sex distribution did not moderate the effects. Later publication year was 
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associated with a smaller increase in QOL. We do not have a convincing explanation for this 
finding, but note that it is in line with the observation that effect sizes in clinical trials tend to 
decrease over time (Ioannidis, 2005; Johnsen, & Friborg, 2015).
There are several limitations that should be considered when interpreting these findings. 
First, despite the relatively large number of clinical trials of one of the most common mental 
health problems, we identified just two studies that directly examined the effects of SSRI 
and CBT for depression on QOL, and no study examined the combined effect on QOL. 
Therefore, we cannot conclude that, despite the lack of significant differences, SSRIs and 
CBT are as effective for improving QOL. Without a direct comparison of these modalities, it 
is not possible to control the various potential factors that might mediate and moderate the 
effects, leaving the results to be tentative. This is clearly an area for future research, and 
would enable more robust examinations of differential efficacy. Second, a limited number of 
studies had control conditions to use as a comparison for the effects of CBT or SSRIs, and 
the pooled effect sizes for such studies was rather small. This makes it difficult to establish 
whether such effects are specific to the treatments examined in this study. A recent meta-
analysis by Kolovos et al. (2016), for instance, found no difference between the effect of 
CBT and other forms of psychotherapy on quality of life in depression, further underscoring 
the need for more comparative studies. Moreover, there were not enough studies to conduct 
a moderator analysis to examine differences in effect size across type of control group.
Third, only CBT studies reported data at follow-up, thus the long-term effect of SSRIs on 
QOL could not be examined. Fourth, only one SSRI study reported data on psychiatric 
comorbidity. Again, this confound does not allow for a direct comparison between the 
effects of CBT and SSRI on QOL. Fifth, in some instances, results of the moderator analyses 
were based on a small number of studies. Relatedly, the effects of the two treatment 
modalities on QOL might be different between patients with and without certain other 
comorbid conditions (e.g., cardiovascular disease, pain, cancer, etc), because the treatments 
might have different effects of these conditions, thereby differentially improving QOL. 
Many more large-scale trials would be needed to control for all these potentially 
confounding factors. Sixth, although the risk of bias was not related to effect sizes, the 
sample of included studies was relatively small and there is no measure or procedure that 
can perfectly detect and correct publication bias. Therefore, it is difficult, if not impossible, 
to accurately detect the number of unpublished studies or their magnitude on the overall 
estimate of treatment effects. Finally, there was some level of heterogeneity in the measures 
used to assess QOL. While measures that primarily focused on symptoms or health status 
without assessing satisfaction with one’s life were excluded in accordance with prior 
conceptualizations of QOL (Moons, Budts, & De Geest, 2006; Smith, et al., 1999), 
instruments still varied to some degree (e.g., different emphases on satisfaction with physical 
vs. psychological functioning).
Despite these limitations, our results add to the current state of knowledge regarding the 
effect of CBT and SSRIs for depression on QOL. Our review suggests that both treatment 
modalities improve QOL in patients with depression, with no evidence for differential 
effects between treatments. Improvements in QOL were more strongly linked to symptom 
reduction after CBT than SSRIs, possibly pointing to a different mechanism through which 
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the treatments enhance QOL. However, in order to directly compare CBT and SSRIs for 
depression on QOL, large-scale studies are needed that directly compare these treatment 
modalities (and their combination).
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Figure 1. 
Flow diagram of study selection process
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Figure 2. 
Funnel plot of precision by Hedges’ g for quality of life measures in the pooled meta-
analysis.
Note: This funnel plot reflects a random effects model. Horizontal and vertical axes plot the 
effect size and standard error of the effect size, respectively.
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